Search Results for: Screening del cancro al seno nelle donne

This cross-sectional study investigates the prevalence of up-to-date lung cancer screening across the 50 US states and the District of Columbia in 2022.

In the Original Investigation titled “Mail-Order Pharmacy Dispensing of Mifepristone for Medication Abortion After In-Person Screening,” published online on May 13, 2024, in JAMA Internal Medicine, Table 2 was updated to change 3 less-than symbols to less-than-or-equal-to symbols. This article was corrected online.

This randomized clinical trial examines whether patient navigation improves lung cancer screening completion among people experiencing homelessness.

The National Lung Screening Trial, a landmark randomized clinical trial that demonstrated the efficacy of lung cancer screening with low-dose computed tomography (LDCT), was published more than a decade ago. In the interim, the US Preventive Services Task Force has endorsed lung cancer screening in certain adults, insurance coverage of LDCT has expanded, and a second large randomized clinical trial, the NELSON trial, demonstrated that LDCT can reduce lung cancer mortality. Importantly, annual LDCT screening also carries risks. In a recent observational study, approximately 32% of those screened underwent additional imaging, 3% had invasive testing, and 31% of those who received invasive testing had a complication.

This cross-sectional study estimates positive screening rates for 4 social risk factors and assesses federally qualified health center characteristics associated with higher positive screening rates.

New England Journal of Medicine, Volume 391, Issue 5, Page 468-474, August 1, 2024.

Scopo del progetto, del valore di 10 milioni di euro di cui 3,8 finanziati da Regione Lombardia, è l’aggiornamento tecnologico del sincrotrone per produrre elio, ossigeno e litio

Objectives
The incidence of chronic kidney disease (CKD) is increasing owing to the ageing population, resulting in an increased demand for dialysis and kidney transplantation, which can be costly. Current research lacks clarity regarding the relationship between residence setting and CKD prevalence or its related risk factors. This study explored the urban–rural disparities in CKD prevalence and risk factors in Taiwan. Our findings will aid the understanding of the distribution of CKD and the design of more effective prevention programmes.

Design
This cross-sectional community-based study used the Renal Value Evaluation Awareness and Lift programme, which involves early screening and health education for CKD diagnosis and treatment. CKD prevalence and risk factors including alcohol consumption, smoking and betel nut chewing were compared between urban and rural areas.

Setting
Urbanisation levels were determined based on population density, education, age, agricultural population and medical resources.

Participants
A total of 7786 participants from 26 urban and 15 rural townships were included.

Results
The prevalence of CKD was significantly higher in rural (29.2%) than urban (10.8%) areas, representing a 2.7-fold difference (p

Costi insostenibili per molti,fino a 48mila euro per tumore seno

Celiac disease (CD) is a common yet underdiagnosed autoimmune disease with substantial long-term consequences. High-accuracy point-of-care tests (POCTs) for CD antibodies conducted at youth primary healthcare centers (YHCCs) may enable earlier identification of CD, but evidence about the cost-effectiveness of such strategies is lacking. We estimated the long-term cost-effectiveness of active case-finding and mass-screening compared to clinical detection in the Netherlands.

Oggi la Giornata mondiale, fondamentale lo screening preventivo

Relazione al Parlamento. Schillaci, ‘fenomeno resta criticità’

Nuovo ambulatorio attivo per donne a Villa Igea e Villa Serena

Survey results suggest that many women might prefer to delay screening.

Introduction
Obstructive sleep apnoea (OSA) is a common, but underdiagnosed, sleep disorder. If untreated, it leads to poor health outcomes, including Alzheimer’s disease, cancer, cardiovascular disease and all-cause mortality. Our aim is to determine the feasibility and cost-effectiveness of moving the testing for OSA into general practice and how general practitioner (GP)-based screening affects overall detection rates.

Methods and analysis
Randomised controlled trial of case finding of OSA in general practice using a novel Medicines and Healthcare products Regulatory Agency-registered device (AcuPebble SA100) compared with usual care with internal feasibility phase. A diverse sample of general practices (approximately 40) from across the West Midlands Clinical Research Network will identify participants from their records. Eligible participants will be aged 50–70 years with body mass index >30 kg/m2 and diabetes (type 1 or 2) and/or hypertension (office blood pressure >145/90 mm Hg or on treatment). They will exclude individuals with known OSA or chronic obstructive pulmonary disease, or those they deem unable to take part. After eligibility screening, consent and baseline assessment, participants will be randomised to either the intervention or control group. Participants in the intervention arm will receive by post the AcuPebble sleep test kit. Those in the control arm will continue with usual care. Follow-up questionnaires will be completed at 6 months. The study is powered (90%) to detect a 5% difference and will require 606 patients in each arm (713 will be recruited to each arm to allow for attrition). Due to the nature of the intervention, participants and GPs will not be blinded to the allocation.

Outcomes
Primary: Detection rate of moderate-to-severe OSA in the intervention group versus control group. Secondary: Time to diagnosis and time to treatment for intervention versus control group for mild, moderate and severe OSA; cost-effectiveness analysis comparing the different testing pathways.

Ethics and dissemination
The trial started on 1 November 2022. Ethical approval was granted from the South Central Oxford A Research Ethics Committee on 9 June 2023 (23/SC/0188) (protocol amendment version 1.3; update with amendment and approval to renumber to V2.0 on 29 August 2023). Patient recruitment began on 7 January 2024; initial planned end date will be on 31 April 2025.
Results will be uploaded to the ISRCTN register within 12 months of the end of the trial date, presented at conferences, submitted to peer-reviewed journals and distributed via our patient and public involvement networks.
The University of Warwick will act as the trial sponsor. The trial will be conducted in accordance with the Sponsor and Primary Care Clinical Trials Unit standard operating procedures.

Trial registration number
ISRCTN 16982033.